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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S37articular antigen leads to additional pain-related behaviours. This
approach should enable us to dissect relationships between speciﬁc
pain pathways and joint pathology.
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PAIN SIGNALLING IN RODENT JOINTS BY SERINE PROTEASES
J.J. McDougall, A. Reid, F.A. Russell. Dalhousie Univ., Halifax, NS, Canada
Purpose: Serine proteases modulate pain by either activating or dis-
arming protease-activated receptors (PARs). The aim of the present
study was to assess the effect of two serine proteases (cathepsin G and
neutrophil elastase) on knee joint mechanosensitivity and pain in
rodents.
Methods: Electrophysiological recordings from knee joint primary
afferents were carried out in deeply anaesthetised male Wistar rats in
response to normal and hyper-rotation of the knee. Animals were
treated with either normal or denatured cathepsin G (1ng - 10mg; close
intra-arterial injection) and nerve recordings repeated. In separate
experiments, the effect of intra-articular injection of human neutrophil
elastase (1-50mg rat; 1-5mg mouse) on pain behaviour in awake and
unrestrained Wistar rats and c57bl/6 mice was determined by meas-
urement of hindlimb incapacitance (weight bearing) and von Frey hair
tactile allodynia.
Results: Peripheral administration of cathepsin G caused a dose-
dependent reduction in joint mechanosensitivity compared to boiled
enzyme, which had no discernible effect (P<0.05). The desensitizing
effect of cathepsin G occurred with both normal and hyper-rotation of
the knee, with the top dose of the enzyme reducing afferent activity by
around 75%. Intra-articular injection of neutrophil elastase produced a
signiﬁcant (P<0.05) pain behavioural response in both rats and mice
lasting several hours.
Conclusions: Cathepsin G reduced joint mechanosensitivity, probably
by disarming PAR4 (which is pro-nociceptive), or activating PAR1, which
is known to be anti-nociceptive in joints. Local injection of neutrophil
elastase produced a robust pain response in rats and mice, possibly by
activating PAR2. Future studies will determine the distinct PAR path-
ways involved in protease-induced pain regulation in arthritic joints.
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Purpose: Patient reported outcomes (PROs) are used across medical
disciplines to follow the course of a disease or evaluate the results of
interventions, with regulatory agencies such as the US Food and Drug
Administration requiring their use in medical product development.
Since its publication in 1998, the ‘Knee Injury and Osteoarthritis Out-
come Score’ (KOOS) has been widely utilised as a PRO in clinical and
research evaluation of knee injuries and osteoarthritis (OA), with more
than 77,000 unique patient datasets available in international registries.
However, no studies to date have summarised the measurement
properties of the KOOS across the available literature, or subjected
individual studies to quality rating. The purpose of this study was to
conduct a systematic review and meta-analysis of KOOS measurement
properties.
Methods: In accordance with PRISMA guidelines, a search strategy
incorporating terms for “KOOS” and “knee” was used to search six
electronic databases with no language restrictions, with the ﬁnal search
conducted on 6th February 2013. Additional papers were identiﬁed
from reference lists and the KOOS website. Two independent reviewers
utilised deﬁned criteria to screen for eligibility: i) primary aim was to
evaluate at least one measurement property of the KOOS or KOOS-PS
(physical function short-form) (e.g. reliability, validity, responsiveness,
interpretability); ii) inclusion of participants of any age suffering from
any knee condition, and/or asymptomatic controls; and iii) KOOS orKOOS-PS were patient-completed. Included studies underwent meth-
odological quality assessment using the COSMIN Checklist by two
independent reviewers. A third reviewer was consulted for discrep-
ancies. Extracted data for test-retest reliability, internal consistency, and
hypothesis testing was pooled where appropriate, using generic inverse
variance (random effects) methodology. Reliability statistics (ICC val-
ues) were analyzed as Fisher-transformation of a correlation coefﬁcient;
having an approximate normal distribution with an estimable standard
error. Inconsistency was assessed via I-squared (I2). This was performed
for all studies (overall), and for subgroup analyses based on participant
age, condition, intervention and language. Qualitative evidence syn-
thesis was performed where data pooling was not possible.
Results: 954 unique records were identiﬁed by the search strategy, with
85 full-text articles assessed for eligibility. 30 studies evaluating 17
different language versions of KOOS, and including more than 5000
participants (mean age range 26 to 77 years), met all eligibility criteria
and were included in subsequent analyses. Studies evaluated partic-
ipants with knee injuries (ACL, meniscus, focal cartilage lesion) or OA,
who underwent no intervention or exercise, weight loss, pharmaco-
logical, and surgical interventions. Pooled estimates for test-retest
reliability from 23 very heterogeneous cohort ﬁndings ranged from 0.84
(sport/recreation subscale [95%CI: 0.78 to 0.88; I2¼87%]) to 0.9 (activ-
ities of daily living [ADL] subscale [0.86 to 0.92; I2¼84%]). Overall, KOOS
subscales demonstrated adequate convergent and divergent construct
validity in comparisonwith the SF-36. KOOS subscales showed stronger
correlations with SF-36 bodily pain (mean r 0.45 to 0.69) and physical
function (0.42 to 0.65) than with role-emotional (0.18 to 0.31) and
mental health (0.04 to 0.33). Responsiveness data was available for 15
unique cohorts, although none followed COSMIN recommendations for
hypothesis testing. KOOS subscales demonstrated largest effect sizes at
3 to 36 months for surgical interventions (ACL reconstruction, cartilage
repair, total knee replacement) (mean effect size pain 1.63; symptoms
0.91; ADL 1.57; sport/recreation 1.19; quality of life 1.78). Only one study
calculated the minimal important change (pain 11.2, symptoms 11.8,
ADL 11.1, sport/recreation 12.1, quality of life 8.7).
Conclusions: Overall, data from meta-analysis revealed that KOOS
demonstrates adequate test-retest reliability for groups (>0.8). As
expected, KOOS is more strongly correlated with physical subscales of
the SF-36 across different conditions, interventions and languages.
While KOOS demonstrates large effect sizes post-surgery, future studies
should prioritise evaluation of longitudinal validity to adhere with
updated recommendations for evaluation of measurement properties.
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ALL-CAUSE MORTALITY AND SERIOUS CARDIOVASCULAR EVENTS IN
PEOPLE WITH HIP AND KNEE OSTEOARTHRITIS: A POPULATION
BASED COHORT STUDY
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Purpose: Osteoarthritis (OA) is under-treated in part due to the high co-
prevalence of other chronic conditions. Approximately 90% of people
aged 65þ years with symptomatic OA have at least one additional
chronic condition; OA and cardiovascular disease, CVD, are among the
most common dyads seen in clinical practice. CVD, in particular, may be
perceived as precluding the use of OA therapies (e.g. NSAIDs). Inad-
equately treated, people with OA may manage their OA by avoiding
activities, like walking, that exacerbate symptoms. Reduced physical
activity may further increase these individuals’ CVD risk. We therefore
examined the contribution of OA disability to other CVD risk factors,
including prior history of a CVD event, on risk for CVD events.
Methods: This retrospective cohort study used data from a population
cohortwith symptomatic hip and kneeOA that was recruited from 1996-
98 through a screening survey of 100% of the population aged 55þ years
in twoOntario regions (n¼2225hadOAconﬁrmedonexamination andx-
ray). The baseline survey assessed: socio-demographics; smoking; self-
reportedheight,weight andNSAIDuse; comorbidity (includingphysician
diagnosis and treatment in thepast year forhighbloodpressure, diabetes,
andheartproblems); andmentalhealth status.OAdisabilitywas assessed
using theWOMAC function subscale, useof awalkingaid (yes/no) and the
Health Assessment Questionnaire walking disability subscale (0–3;
higher scores indicate greater disability). The current study used baseline
surveys linked to provincial health administrative databases.
